Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.

Ibrutinib reduced T-cell abundance but increased T-cell activation Ibrutinib monotherapy led to an overall trend of reduced frequencies of all CD3 + T cells, including subsets such as CD4 + T cells, CD8 + T cells, and regulatory T cells (Tregs) in blood ( online supplemental figure 6A ).

also in 4,871 other papers

In the immune response arm ( online supplemental figure 1B ), ibrutinib monotherapy reduced B-cell frequency in the blood on average when compared with the frequency pretherapy ( figure 1B , left panel), although this did not reach statistical significance.

also in 111,027 other papers